Genetic instability and tumor cell variation: Implications for immunotherapy

Fenton, Robert G.; Longo, Dan L.
February 1995
JNCI: Journal of the National Cancer Institute;2/15/95, Vol. 87 Issue 4, p241
Academic Journal
Discusses the implications of immunotherapy in genetic instability and tumor cell variation. Nature of cancer as a genetic disease; Efficacy of immunotherapy in cancer treatment; Difficulty in inducing antitumor responses; Observing I MHC allospecificities in tumor histologies; Tumor escape mechanisms in formulating effective immunotherapy approaches; Activation of multiple effector pathways.


Related Articles

  • Development of cancer immunotherapies based on identification of the genes encoding cancer... Rosenberg, Steven A. // JNCI: Journal of the National Cancer Institute;11/20/96, Vol. 88 Issue 22, p1635 

    Presents a study on the development of cancer immunotherapies based on the identification of genes encoding cancer regression antigens. Molecular identification of tumor antigens; Generation of antitumor effector cells; Implications on the development of cancer immunotherapies.

  • Taking advantage of the body's healing power. Ward, Darrell E. // USA Today Magazine;May95, Vol. 123 Issue 2600, p68 

    Discusses immunotherapy in the treatment of cancer. Key to making immunotherapy succeed; Description and functions of the immune system; Components of the immune system; Distinctions between normal and cancerous cells; Gene therapy research.

  • Immune effects of a short-term intervention for cancer patients. Fawzy, Fawzy I. // Advances: The Journal of Mind-Body Health;Fall94, Vol. 10 Issue 4, p32 

    Studies the immune effects of a short-term intervention for cancer patients. Strengthening of the coping abilities of the patients; Description of the intervention program; Other effects of the intervention.

  • Made-to-measure vaccine overwhelms cancer cells. Berger, Abi // New Scientist;7/15/95, Vol. 147 Issue 1986, p8 

    Reports on the designer DNA vaccines developed by scientists at Southampton University Hospital and at the Centre for Protein Engineering in Cambridge, England to attack particular cancers. Injection of plasmids containing the DNA sequence codes for a specific cancer into the patient's muscles...

  • Cancer immunotherapy: potential involvement of mediators. Ben-Efraim, S. // Mediators of Inflammation;Jun97, Vol. 6 Issue 3, p163 

    The description of a cell-free soluble anti-tumour factor by Carswell et al. in 1975 (Proc Natl Acad Sci USA, 72: 3666 - 3670) was followed by a long series of experimental and clinical investigations into the role of cell-free mediators in cancer immunotherapy. These investigations included...

  • Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability. Epstein, Alan L.; Mizokami, Myra M.; Jiali Li; Peisheng Hu; Khawli, Leslie A. // JNCI: Journal of the National Cancer Institute;5/21/2003, Vol. 95 Issue 10, p741 

    Background: The cytokine interleukin 2 (IL-2) is involved in the activation of T cells and has been shown to play a central role in cancer immunotherapy. The full therapeutic potential of IL-2, however, has not been realized because of its doselimiting systemic toxicity. We sought to identify a...

  • Tumour surveillance: Missing peptides and MHC molecules. KHANNA, RAJIV; Khanna // Immunology & Cell Biology;Feb1998, Vol. 76 Issue 1, p20 

    Immunotherapy involving CTL is an attractive alternative for treatment of various malignancies. One of the approaches currently being explored for immune targeting of human cancers involves potentiation of immunogenicity of malignant cells by gene transduction. This strategy is undoubtedly...

  • WT1 as a Novel Target Antigen for Cancer Immunotherapy. Oka, Y.; Tsuboi, A.; Elisseeva, O.A.; Udaka, K.; Sugiyama, H. // Current Cancer Drug Targets;Mar2002, Vol. 2 Issue 1, p45 

    Wild-type Wilms' tumor gene WT1 is expressed at high levels not only in most of acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, but also in various types of solid tumors including lung cancer. We tested the ability of the gene product (WT1) to serve as a target antigen for...

  • Melanoma immunotherapy trial shows some improvement in survival. Hilton, Lisette // Dermatology Times;Sep2002, Vol. 23 Issue 9, p43 

    Focuses on the use of immunotherapy trials with vaccinia viral melanoma cell lysates in patients with cancer in Australia. Comparison of immunotherapy with vaccinia melanoma cell lysates; Difference in the median survival of melanoma patients; Effects of immunotherapy as an adjuvant melanoma...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics